恒瑞医药：收到创新型抗肿瘤药物HRS-2329片临床试验批准通知书 目前国内外尚无同类药物获批上市

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-2329 tablets in patients with advanced solid tumors carrying RAS mutations or amplifications [1] Group 1: Company Developments - HRS-2329 tablets are an innovative anti-tumor drug independently developed by the company, with no similar drugs approved for market domestically or internationally [1] - The total research and development investment for the related project has reached approximately 60.15 million yuan [1] Group 2: Regulatory and Market Context - Following the approval of the clinical trial notification, the drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be produced and marketed [1]